Recent Updates
Recently added Catalysts
NKTR

Nektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare Conference in New York City Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Piper Jaffray 29th Annual...

Key Takeaway: SAN FRANCISCO , Nov. 27, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that its corporate presentation will be webcast at the upcoming Piper Jaffray 29 th Annual Healthcare Conference in New York City on Tuesday, November 28, 2017 at 5:10 p.m. ET. The

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+186%
120-day peak, hindsight
Typical move
10.2%
average across 4 past catalysts
Cash runway
~40 mo
Minimal dilution risk
Lead asset
Rezpegaldesleukin
Phase 3 · Moderate-to-Severe Atopic Dermatitis

Full Press Release Details

SAN FRANCISCO , Nov. 27, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that its corporate presentation will be webcast at the upcoming Piper Jaffray 29 th Annual Healthcare Conference in New York City on Tuesday, November 28, 2017 at 5:10 p.m. ET.
The presentation will be accessible via a Webcast through a link posted on the Investors, Events Calendar section of the Nektar website: http://ir.nektar.com/events.cfm . This Webcast will be available for replay until December 29, 2017.
Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .
Last updated: Nov 27, 2017